Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.
Raghav KPS, Guthrie KA, Tan B Jr, Denlinger CS, Fakih M, Overman MJ, Dasari NA, Corum LR, Hicks LG, Patel MS, Esparaz BT, Kazmi SM, Alluri N, Colby S, Gholami S, Gold PJ, Chiorean EG, Kopetz S, Hochster HS, Philip PA.
Raghav KPS, et al. Among authors: hicks lg.
J Clin Oncol. 2025 Jan 6:JCO2401710. doi: 10.1200/JCO-24-01710. Online ahead of print.
J Clin Oncol. 2025.
PMID: 39761503